ARCHIVES

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

This article is from The Cancer Letter archive.

Vol. 17 No. 31 | August 2, 1991

Download PDF Visit The Full Archive

Related Articles

Professional Societies: FASEB Urges Increase Of 15% For NIH, Double In Five Years

March 6, 1998

T-Cell Vaccines Cut Time To Protective Immunity

November 25, 2005

Niederhuber: Clinical Trials System Must Refocus To Emphasize Translational Studies.

July 9, 2010

FDA, NCI Near Agreement On Handling INDs

January 28, 1977

NSABP Breast Cancer Prevention Trial Reports Final Results On Tamoxifen

November 25, 2005

Breast Cancer Funding: Shalala Approves Agreement Over Disputed $14 Million

August 8, 1997